Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VivoVec CD20
- Development stage
- Unknown
- Lead developer
- Umoja Biopharma
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
VivoVec CD20 is an innovative in vivo chimeric antigen receptor (CAR) T-cell therapy developed by Umoja Biopharma. Utilizing the proprietary VivoVec lentiviral vector platform, the therapy is designed to generate anti-CD20 CAR-T cells directly within the patient's body, bypassing the traditional requirements for ex vivo manufacturing and lymphodepleting chemotherapy. The therapy consists of surface-engineered lentiviral particles that are administered systemically to target and transduce T cells in situ. Once transduced, these T cells express a CAR specific for CD20, a protein found on the surface of B cells, leading to the targeted destruction of malignant or pathogenic B cells. VivoVec CD20 is being developed for the treatment of B-cell malignancies (as UB-VV100) and autoimmune diseases (as UB-VV111), offering a potentially more accessible and scalable alternative to conventional CAR-T cell therapies.
- Other names
- VivoVec-CD20VivoVec-CD-20VivoVec-CD 20
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)CD80 (T-lymphocyte activation antigen CD80)CD58 (Leukocyte function-associated antigen 3)
Beyond the preview
Go deeper on VivoVec CD20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VivoVec CD20.